Patent ID: 8889188

Claim:
A low power three-dimensional (3D) self-assembled conducting photoluminescent nanomedicine, comprising: 3D unitary, binary, ternary, and quaternary nanomedicine crystals of isoprenaline, adenosine triphosphate, verapamil, and superoxide dismutase, in a L 16 (2) 15 test protocol that includes four unitary groups, six binary groups, four ternary groups and one quaternary group at two levels of 0 and 1, and a L 9 (3) 4 test protocol that includes nine quaternary groups at three levels of 1, 2 and 3, the 3D unitary, binary, ternary, and quaternary nanomedicine crystals disposed on a substrate of graphite and/or silicon, wherein the 3D unitary, binary, ternary, and quaternary nanomedicine crystals have a length from 400 nm to 1000 nm, a width from 400 nm to 1000 nm, and a height from 0.3 nm to 95 nm, and the low power three-dimensional (3D) self-assembled conducting photoluminescent nanomedicine has an inelastic electron tunneling property, a conducting property having a range of 1-8 μeV, and a photoluminescent property having a maximum photoluminescence intensity at 2000 absorbance units, a photoluminescence bandwidth covering 450-750 nm, and a central photoluminescence peak being located around 550 nm after subtraction of a background signal.